- Home
- HNVR vs TNYA Comparison
HNVR vs TNYA Comparison
Compare HNVR & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNVR
- TNYA
- Stock Information
- Founded
- HNVR 2008
- TNYA 2016
- Country
- HNVR United States
- TNYA United States
- Employees
- HNVR N/A
- TNYA N/A
- Industry
- HNVR Commercial Banks
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- HNVR Finance
- TNYA Health Care
- Exchange
- HNVR Nasdaq
- TNYA Nasdaq
- Market Cap
- HNVR 129.7M
- TNYA 138.1M
- IPO Year
- HNVR 2022
- TNYA 2021
- Fundamental
- Price
- HNVR $23.74
- TNYA $1.67
- Analyst Decision
- HNVR Buy
- TNYA Strong Buy
- Analyst Count
- HNVR 1
- TNYA 4
- Target Price
- HNVR $22.00
- TNYA $17.33
- AVG Volume (30 Days)
- HNVR 44.0K
- TNYA 7.5M
- Earning Date
- HNVR 01-22-2025
- TNYA 11-06-2024
- Dividend Yield
- HNVR 1.69%
- TNYA N/A
- EPS Growth
- HNVR N/A
- TNYA N/A
- EPS
- HNVR 1.85
- TNYA N/A
- Revenue
- HNVR $64,015,000.00
- TNYA N/A
- Revenue This Year
- HNVR N/A
- TNYA N/A
- Revenue Next Year
- HNVR $16.84
- TNYA N/A
- P/E Ratio
- HNVR $12.84
- TNYA N/A
- Revenue Growth
- HNVR 6.86
- TNYA N/A
- 52 Week Low
- HNVR $13.62
- TNYA $0.99
- 52 Week High
- HNVR $27.14
- TNYA $7.01
- Technical
- Relative Strength Index (RSI)
- HNVR 46.22
- TNYA 37.59
- Support Level
- HNVR $23.06
- TNYA $0.99
- Resistance Level
- HNVR $26.24
- TNYA $3.69
- Average True Range (ATR)
- HNVR 1.10
- TNYA 0.40
- MACD
- HNVR -0.27
- TNYA -0.27
- Stochastic Oscillator
- HNVR 16.67
- TNYA 22.59
About HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.